Health · Pharma & Biotech · 2 hrs ago
Idorsia presents new findings on blood pressure drug aprocitentan
Idorsia presented new findings on aprocitentan, a drug for severe high blood pressure, at an American Heart Association conference.
The findings came from further analyses of the phase III Precision trial.
They focused on people with obesity and people with heart, kidney and metabolic conditions at the same time.
In both groups, the drug quickly lowered blood pressure by a double-digit amount, Idorsia said.
The analyses also found signs that it may help protect the kidneys.
Aprocitentan is approved for severe high blood pressure in the United States, the European Union, the United Kingdom, Switzerland and Canada.
It is sold as Tryvio in the United States and Jeraygo in the other listed markets.
Idorsia presented new findings on its blood pressure drug aprocitentan at the American Heart Association congress.
The findings came from further analyses of the Phase III Precision study of difficult-to-treat high blood pressure.
The analyses examined people with obesity and patients with co-occurring heart, kidney and metabolic diseases.
In both groups, aprocitentan led to a rapid, double-digit reduction in blood pressure, Idorsia said.
The company also reported indications of a kidney-protective effect.
Aprocitentan is approved for severe high blood pressure under different brand names in several countries and regions.
- Who
- Idorsia presented the findings.
- What
- The company shared further analyses of aprocitentan, a drug for severe high blood pressure.
- When
- Monday; the article was published on 2026-10-12.
- Where
- At the American Heart Association congress.
- Why
- The analyses examined the drug’s effects in people with obesity and patients with heart, kidney and metabolic diseases.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
The analyses drew on the study of aprocitentan in difficult-to-treat high blood pressure.
Idorsia said the analyses found rapid, double-digit blood pressure reductions in both patient groups and indications of a kidney-protective effect.
cash.ch published its report on Idorsia’s presentation.
- Drug
- Aprocitentan
- Study
- Phase III Precision
- Patient groups
- People with obesity; patients with heart, kidney and metabolic diseases
- Reported blood pressure effect
- Rapid, double-digit reduction in both groups
- US brand name
- Tryvio
- Brand name in the EU, UK, Switzerland and Canada
- Jeraygo
Sources
Related news
Personalized cancer vaccine succeeds in phase 3 melanoma trial
Pilot trial tests support to limit weight regain after GLP-1 drugs stop
Dong-A launches three ibuprofen-based cold medicines
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Spain withdraws five erectile dysfunction supplements containing undeclared drugs
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
